SGLT2 inhibitors, drugs which are used to treat type 2 diabetes, reduce the risk of heart failure and death, according to a major Scandinavian registry study led from Karolinska Institutet, published in The BMJ.
Cardiovascular disease is a serious complication of type 2 diabetes. The new SGLT2 inhibitors, which are now a commonly used drug group, reduce blood glucose. Clinical studies have also shown that these drugs can reduce the risk of cardiovascular disease.
However, it is unclear whether these findings also mean that there are positive cardiovascular effects from SGLT2 inhibitors in a broader patient group. This has now been investigated in a study published in The BMJ.
This information was then compared with an equally sized matched population who began treatment with a different diabetes drug, a DPP4 inhibitor. The primary outcomes in the study were major cardiovascular events (defined as myocardial infarction, stroke or cardiovascular death) and hospital admission for heart failure. An important secondary outcome was any-cause death.
In the primary analysis, the patients were monitored throughout the follow-up period, regardless of whether they had completed their treatment. The researchers found that the use of SGLT2 inhibitors was associated with a reduced risk of heart failure but not with major cardiovascular events. The risk of heart failure was 34 per cent lower in the SGLT2-inhibitor group than in the DPP4-inhibitor group. The use of SGLT2 inhibitors was also linked to a 20 per cent lower risk of death.
In an additional analysis the researchers studied the risks only when the patients took the drug and found a reduced risk of both heart failure and major cardiovascular events.
"Our study suggests that there is cardiovascular benefit from SGLT2 inhibitors for a broader patient group in routine clinical care," says principal investigator Björn Pasternak, associate professor at Karolinska Institutet's Department of Medicine in Solna. "This is an important result that we believe may be of interest to patients as well as drug authorities and doctors."
The results are applicable primarily to dapaglifozin, which was the predominant SGLT2 inhibitor used in Scandinavia during the study period.
The study is an observational study, which means that causality cannot be established.